Unlock the unparalleled immunoassay sensitivity that is revolutionizing research capabilities. Learn how the Simoa HD-X Analyzer® provides up to 1000x greater sensitivity than traditional methods: bit.ly/3K6KwXn

#Simoa #Immunoassay #Research

The #Alzheimers diagnostic and care landscape is rapidly evolving. Healio recently spoke with Quanterix CEO Masoud Toloue about these shifts and the next steps for making AD blood tests more widely accessible: bit.ly/3URH6wJ

#Cancer therapy-associated neurotoxicity can negatively affect patients and the course of treatment. Explore the latest studies working to meet the critical need for accurate biomarker tests that could predict toxicity onset and assess severity. 📚⬇️

Deciphering #neurological disorders early on remains a challenge 🧠 Symptoms are subtle, assessments subjective, and definitive tests scarce, but #biomarkers like p-Tau 181 are offering hope in #AlzheimersDisease diagnosis. Explore our research below.

#DYK the integration of p-Tau 181 as a biomarker was key to enabling the development and approval of lecanemab as an innovative #Alzheimers disease treatment? Throughout clinical settings, blood-based biomarkers have emerged as a powerful tool. ➡️ bit.ly/49EOJMe

Congrats to Dr. Al-Khleifaton and the full team at Institute of Psychiatry, Psychology & Neuroscience! We look forward to seeing the breakthroughs led by your team.

King's College London #Biomarkers #PrecisionMedicine #DiagnosticResearch

🧠 Where is your #neurology research focused?

Neuro #biomarkers like GFAP, p-Tau 213, & more are linked with conditions like Alzheimer’s, dementia, and TBI. Take our poll to share your focus area and explore new Simoa® Assay Kits: bit.ly/3Uzef0

Tune in to an insightful on-demand webinar unraveling #Alzheimers disease alongside Dr. Andy Liu from Duke University and Dr. Blaine Roberts from Emory University. Explore the latest in AD diagnostics and the promise of emerging biomarkers. bit.ly/3VA8phg

🇪🇸 Dive into the heart of neuroscientific innovation at the Simoa® Roadshow Symposium in Leioa, Spain, hosted by Ʌʗʜʋʗɑɼɼʘ.

Explore the latest advancements in #biomarker technologies and get an exclusive lab tour to experience Simoa firsthand! bit.ly/4b8wYH0

Unlock precise monitoring in therapeutic research with IL-17A. Vital for autoimmune, #oncology , and immuno-oncology studies, Simoa technology enables inflammation tracking via IL-17A for research success. Read more below and explore the assay here ➡️ bit.ly/4biFr9V

This #StrokeAwarenessMonth , we're spotlighting breakthroughs in stroke monitoring. Recent research suggests leveraging EEG and blood NfL levels for comprehensive tracking could be beneficial for patient care and follow-up. 🧠💪 bit.ly/49VaLKV

#StrokeRecovery #Neurology

🧠 The introduction of p-tau 217 LDTs marks a pivotal moment in Alzheimer's care. Powered by Simoa® technology, these tests offer physicians a valuable tool to aid in patient diagnosis. Catch up on the latest in AD diagnostics: bit.ly/3JaGZXR

C&EN (Chemical & Engineering News) #Alzheimers

#ICYMI we are thrilled to be collaborating with five prominent health networks to expand access to Alzheimer’s blood biomarker tests. With 140+ hospitals across 18 states represented, we're making significant strides in #Alzheimers care. bit.ly/48RAiUP

#Healthcare

Did you know sTREM2 may be linked to Parkinson’s disease? Elevated sTREM2 levels in plasma and CSF correlate with disease progression, hinting at its potential as a biomarker.

#Parkinsons #Biomarkers #Parkinsons AwarenessMonth

Our team had a wonderful time at #AAN2024 🧠

Huge thanks to our team for representing Quanterix and for sharing how ultrasensitive Simoa® technology is advancing neurology research.

Interferon-alpha (IFN-α) is a critical component of our immune system's arsenal against viruses and cancer. Explore in detail how IFN-α is advancing oncology and immunology research. ⬇️

#Cancer #Oncology #ClinicalResearch

Exciting news in Alzheimer's care! Quanterix's Simoa® p-Tau 217 blood test has earned Breakthrough Device designation from the US FDA as a diagnostic aid for #Alzheimers . This pivotal moment in AD research offers new hope for #diagnosis and treatment. bit.ly/3VZnRDz

Blood #biomarkers offer a beacon of hope for improving clinical trial outcomes, guiding therapeutic interventions, and transforming the landscape of care for neurological disorders. Discover how biomarkers are enhancing drug development ➡️ bit.ly/49EOJMe

Exciting news! We're participating in the 12th Alzheimer’s & Parkinson’s Drug Development Summit in Boston, MA from April 23rd-25th, 2024. We'll be diving into groundbreaking research in neurodegenerative diseases.
bit.ly/3vOnz81

#DrugDevelopment #Neurodegeneration

Join us for the next Simoa Roadshow Symposium in Rome 🇮🇹

Explore sessions on #Alzheimers , MS, EVs, and our proprietary Homebrew technology, all showcasing the latest in biomarker detection advancements. Register now: bit.ly/3TXdyNQ
#MultipleSclerosis #Biomarkers #Rome